Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Mordor Intelligence | PRODUCT CODE: 391390

Cover Image

PUBLISHER: Mordor Intelligence | PRODUCT CODE: 391390

Europe Bladder Cancer Therapeutics and Diagnostics Market - Growth, Trends, and Forecasts (2022 - 2027)

PUBLISHED:
PAGES: 70 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4750
PDF & Excel (Team License: Up to 7 Users)
USD 5250
PDF & Excel (Site License)
USD 6500
PDF & Excel (Corporate License)
USD 8750

Add to Cart

The increasing burden of bladder cancer is the major factor driving the market in the European region. According to the estimates of Globocan, bladder cancer ranks fifth among the most frequently diagnosed cancer types, with about 197,105 new cases predicted in 2018 for both sexes, representing around 5% of the total cases. Moreover, increasing awareness about bladder cancer and related therapies is fueling the growth of the European bladder cancer therapeutics and diagnostics market. Apart from these, factors, like increasing awareness about bladder diseases and available therapies and innovations in novel drug development, are also contributing to the growth of the market studied. However, various factors, such as rise in the number of patent expiration is estimated to impede the growth of the studied market.

Key Market Trends

Chemotherapy Segment is Expected to Show Better Growth in the Forecast period.

Chemotherapeutics refers to the utilization of drugs to combat a certain disorder. Chemotherapy is the first choice for bladder cancer treatment. In bladder cancer, the drug is administered either intravesically or directly into the urinary bladder. The non-muscle invasive bladder cancer (NMIBC) treatment is generally performed by chemotherapy and BCG immunotherapy. There has not been much development on bladder cancer chemotherapeutic agents, during the past decade. Furthermore, the incidence of bladder cancer is high among the population, which is expected to drive the market over the forecast period.

Competitive Landscape

The market studied is highly competitive and consists of a number of major players. Companies, like AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Novartis, Pfizer Inc., Sanofi SA, etc. hold a substantial market share in the European bladder cancer therapeutics and diagnostics market.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Product Code: 55838

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Awareness on Bladder Diseases and Available Therapies
    • 4.2.2 Increasing Burden of Bladder Cancer
    • 4.2.3 Innovations in Drug Development
  • 4.3 Market Restraints
    • 4.3.1 Rise in the number of Patent Expirations
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product
    • 5.1.1 By Therapeutics
      • 5.1.1.1 Chemotherapy
      • 5.1.1.2 Immunotherapy
      • 5.1.1.3 Others
    • 5.1.2 By Diagnostics
      • 5.1.2.1 Cystoscopy
      • 5.1.2.2 Bladder Ultrasound
      • 5.1.2.3 Urinalysis
      • 5.1.2.4 Others
  • 5.2 By Cancer Type
    • 5.2.1 Transitional Cell Bladder Cancer
    • 5.2.2 Squamous Cell Bladder Cancer
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 Europe
      • 5.3.1.1 Germany
      • 5.3.1.2 United Kingdom
      • 5.3.1.3 France
      • 5.3.1.4 Italy
      • 5.3.1.5 Spain
      • 5.3.1.6 Rest of Europe

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AstraZeneca PLC
    • 6.1.2 Bristol-Myers Squibb Company
    • 6.1.3 Eli Lilly and Company
    • 6.1.4 F. Hoffmann-La Roche Ltd
    • 6.1.5 GlaxoSmithKline PLC
    • 6.1.6 Novartis International AG
    • 6.1.7 Pfizer Inc.
    • 6.1.8 Sanofi SA
    • 6.1.9 Endo International plc
    • 6.1.10 Janssen Pharmaceutical Companies (Johnson & Johnson)

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!